We have a team of highly dedicated, experienced and knowledgeable formulation and analytical chemists with a proven track record in developing pulmonary and nasal drug products.
Impopharma Canada Ltd. is a Toronto, Canada-based developer of pharmaceutical products and complex formulations focused on inhalation pharmaceutical products (solution and suspension sprays, pMDI and DPI).
Impopharma Inc. was founded in 1996 as a CRO by Hanna Piskorz and Harold Wulffhart in a single office enterprise of ~150 ft², that has grown over a span of 20 years with a footprint of ~15,000 ft² comprised of laboratory, small pilot manufacturing, document storage, sample storage and office space operating within an FDA and Health inspected QMS. In October 2018, Impopharma Inc. was acquired by OBG Pharma Group, the Canadian subsidiary was renamed Impopharma Canada Ltd.
Over the years, Impopharma has acted as an extension of the client’s laboratory, including Top 20 global Rx pharma companies, and has equipped itself with highly specialized equipment, key scientists as well as expertise in many product development strategies in line with current regulatory expectations.
MORE ABOUT OUR EXECUTIVES
Chief Operating Officer
Vien is a Chartered Professional Accountant and holds an Honours Bachelor in Accountancy Studies and a Masters of Accounting from the University of Waterloo.
In her role at Impopharma, Vien oversees the Company’s financial, purchasing, and administrative functions.
Vien has over ten years of experience in finance, accounting, human resources, and IT management for development stage, publicly listed and private pharmaceutical companies. Her transaction experience includes being on both sides of M&A transactions, public and private equity financing, debt financing, and partnering/joint-venture initiatives.
Prior to joining Impopharma, Vien was the Controller at YM Biosciences Inc., Accounting Manager at Nexans North America, and Senior Accountant at KPMG where she performed financial statement and internal control audits for clients mainly in the transportation, manufacturing, and industrial products industries.
Chief Scientific Officer
Dr. David Brown
David received his Bachelor of Pharmacy (Hons.) and Ph.D. in Pharmaceutics from The School of Pharmacy, University of London, United Kingdom. He is a certified Project Management Professional (PMP).
In his role at Impopharma, David oversees all Research & Development activities. This includes project opportunity/feasibility assessment, formulation and process development, device development and characterization, analytical development/testing and providing project management oversight.
David has over 20 years of product development and project management experience which include senior leadership roles with brand, biotech, CDMO and generic pharmaceutical companies.
Prior to joining Impopharma, David was Director, R&D Program Management at Teva Canada Ltd. responsible for portfolio selection, providing technical product development expertise and project management oversight. Previously David was Director, Pharmaceutical Development and led the formulation and process development activities for generic products for the Canadian, European and United States markets. David began his career in respiratory drug development in the UK with Fisons Plc in respiratory physics, dry powder inhaler product development and engineering drug substance characteristics for inhalation.